How US Tariffs on Patented Drugs Could Impact Global Pharma and India’s Exports

In today’s interconnected world, decisions made in one country can ripple across the globe—especially when it comes to critical sectors like pharmaceuticals. Recently, the United States took a significant step by imposing hefty tariffs on patented drugs exported to the US. This move has sparked widespread debate about national security, trade policies, and the future of global pharmaceutical supply chains. Let’s unpack what’s happening, why it matters—particularly for India—and what this could mean for the future.

The Core of the Issue: US Imposes 100% Tariffs on Patent Drugs

The story begins with a major tariff imposition by the US on certain pharmaceutical imports. Specifically, a recent order passed on April 2nd by the US government declared a 100% tariff on all patented drugs exported to the US from various countries. This isn’t just a routine trade tariff; it’s a targeted measure on drugs that are under patent protection.

Why? The US government cites concerns related to national security. A 2025 investigation highlighted the risks of over-dependence on foreign drug supplies, warning that reliance on imports for critical medicines could pose a threat to US security. Essentially, if the US becomes too dependent on other countries for essential drugs, it could face supply disruptions during emergencies or geopolitical conflicts.

Why Are Patented Drugs the Focus?

Patented drugs are typically innovative medicines developed by pharmaceutical companies and protected by patents to recoup their research investments. These drugs often come with higher prices and are crucial for treating complex health conditions. Because they are protected by patents, they are not easily manufactured or copied by generic manufacturers—at least until the patents expire.

In the context of US policies, the tariffs are aimed specifically at these patented drugs, which are often exported from countries like India, China, and various European nations. The rationale is to encourage the US to develop more domestic manufacturing capabilities or to diversify supply chains to reduce dependency.

What Does This Mean for India?

India is often called the “pharmacy of the world” because it exports a massive volume of generic medicines and low-cost drugs to the US and other countries. According to data, by 2025, India’s pharmaceutical exports to the US alone are projected to reach around $97 billion, predominantly consisting of generic drugs.

Since India primarily exports generics—off-patent medicines that are generally not affected by these tariffs—this new US policy puts India in a comparatively safer position. The tariffs target only patented drugs, which constitute a smaller share of India’s exports to the US. Therefore, Indian pharma companies that mainly produce generic medicines are likely to be less impacted, at least in the short term.

However, the move does raise questions about the future of patent protections and the potential for increased tariffs or barriers on patented medicines, which could influence India’s exports of innovative drugs in the longer term.

Is It a Threat to National Security?

Many experts are debating whether these tariffs genuinely pose a national security threat to the US. The US government argues that over-reliance on foreign supply chains for critical medicines could be problematic during crises, such as pandemics or geopolitical conflicts. If foreign countries restrict exports or face manufacturing issues, it could jeopardize the US’s ability to supply essential drugs.

On the other hand, critics argue that such tariffs could lead to higher drug prices for American consumers and stifle innovation by discouraging foreign investment and global collaboration. They also warn that retaliatory measures from other countries could harm global trade relations.

Broader Implications for Global Pharma

This development is part of a broader trend where countries reconsider their dependence on foreign sources for vital medicines and ingredients. It underscores the importance of building resilient, domestic manufacturing capacities while maintaining a balanced global supply chain.

For India, this policy could be a double-edged sword. While it may shield Indian generic exports from immediate impact, it also signals a potential shift in the US’s approach to patent protections and trade policies. Indian pharma companies might need to innovate further, diversify markets, and perhaps even explore developing their own patented drugs to stay competitive.

Final Thoughts: What Should We Keep in Mind?

This recent tariff move by the US highlights the delicate balance between free trade, national security, and economic sovereignty. It raises critical questions:

• Could more countries adopt similar tariffs to safeguard their supply chains?
• How will this impact global drug prices, access, and innovation?
• And what does this mean for India’s position as the world’s pharmacy?

As consumers and stakeholders in global health, it’s essential to stay informed about such policies, as they could shape the future landscape of pharmaceuticals and international trade.

Interested in understanding this complex issue in detail?
Watch the full video to get insights straight from the experts and stay ahead in your UPSC preparation!
Watch the Video Here

Stay tuned, stay curious, and keep learning!